STOCK TITAN

ImmunoGen, Inc. - IMGN STOCK NEWS

Welcome to our dedicated news page for ImmunoGen (Ticker: IMGN), a resource for investors and traders seeking the latest updates and insights on ImmunoGen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ImmunoGen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ImmunoGen's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.4%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.21%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
none
ImmunoGen, Inc.

Nasdaq:IMGN

IMGN Rankings

IMGN Stock Data

8.72B
247.85M
0.32%
86.52%
7.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About IMGN

immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.